Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy-Reference-Cited by-同舟云学术

Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy

Published:2022-10 Issue:10 Volume:34 Page:642-652
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Elumalai T.,Croxford W.,Buijtenhuijs B.,Conroy R.,Sanderson B.,Enting D.,Aversa C.,Doss G.,Das A.,Vasudev N.S.,Kitetere E.,Tolan S.,Law A.,Hoskin P.,Mistry H.,Choudhury A.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference40 articles.

1. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

2. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018

3. Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,2021

4. Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors;Sonpavde;J Urol,2020

5. A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma;Nassar;Br J Cancer,2020

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic models for patients with metastatic urothelial carcinoma: why use them?;Minerva Urology and Nephrology;2023-08

2. Baseline and Dynamic Changes in Hemoglobin Levels Predict Treatment Response and Prognosis in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2023-08

3. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis;Clinical & Experimental Metastasis;2023-06-13

4. Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis;European Urology Focus;2023-03

5. Bladder Cancer: New Insights Into Dose, Volume and Prognostic Biomarkers;Clinical Oncology;2022-10